GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised

Key Takeaways GKOS posted a narrower-than-expected Q2 loss and 29.7% revenue growth, beating the consensus estimate.Revenues were driven by strong uptake of iDose TR and solid performance from Photrexa in corneal health.The company raised 2025 revenue guidance but faces pressure from procedural bundling and coverage limits.Glaukos Corporation (GKOS) reported second-quarter 2025 adjusted loss of 24 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 26 cents. The figure also im ...